The future of cancer immunotherapy: DNA vaccines leading the wayReview Article Published on 2023-06-092024-09-05 Journal: Medical oncology (Northwood, London, England) [Category] update2024, [키워드] adjuvants cancer vaccines combination therapy DNA-based vaccines immune response Immunotherapy Vaccine development [DOI] 10.1007/s12032-023-02060-3 PMC 바로가기 [Article Type] Review Article
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the LiteratureOriginal Article Published on 2023-02-202024-09-05 Journal: Digestive diseases and sciences [Category] update2024, [키워드] biologics combination therapy Inflammatory bowel disease Therapeutics [DOI] 10.1007/s10620-023-07837-0 PMC 바로가기 [Article Type] Original Article
Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!Review Published on 2023-02-012023-06-12 Journal: Antiviral Research [Category] B형 간염, [키워드] combination therapy Direct Acting Antivirals (DAAs) HBsAg seroclearance Hepatitis B virus Host-targeting antivirals (HTAs) Virosuppression. [DOI] 10.1016/j.antiviral.2022.105515 [Article Type] Review
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected miceArticle Published on 2022-12-012023-07-10 Journal: Antiviral Research [Category] COVID19(2023년), [키워드] combination therapy in vivo molnupiravir Nirmatrelvir Remdesivir SARS-CoV-2 [DOI] 10.1016/j.antiviral.2022.105430 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective studyArticle Published on 2022-10-202022-11-15 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] adverse events Algorithm antibody Antiviral antiviral drug antivirals approved benefit Calabria case sery clinical clinical evolution Combination combination therapy combined use coronavirus disease COVID-19 COVID-19 progression drug Early therapies early treatment effective Effectiveness Efficacy escape mutant group Health services hospital Hospital admission hospitalisation Hospitalized hypothesised Immunocompromised immunocompromised individuals implication increase in lesson mAb mAbs malignancy monoclonal antibodies monoclonal antibody monotherapy Patient patients patients treated progression provided receive reduce reported Retrospective study SARS-CoV-2 SARS-CoV-2 genome Support symptom onset Territorial health services. Therapies therapy treated treated patient Treatment [DOI] 10.1186/s12879-022-07774-9 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19Article Published on 2022-10-192022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus [DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesArticle Published on 2022-10-132022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-SARS-CoV-2 anti-spike-IgG antibody Antibody Response baseline benefit blood sample BNT162b2 Cohort combination therapy COVID-19 COVID-19 vaccination COVID-19 vaccine disease Effect elderly patients eligible examined highest humoral immunogenicity identifying immunomodulatory Immunosuppression increased risk Inflammatory medication monotherapy mRNA mRNA vaccine mRNA-1273 Odds ratio outcomes Patient patients provided recruited reduced response rheumatic disease SARS-CoV-2 SARS-COV-2 infection significantly lower spike IgG Support tested the disease the vaccine Treatment Type vaccination vaccine dose waning immunity [DOI] 10.3389/fimmu.2022.1016927 PMC 바로가기
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)Article Published on 2022-09-042022-11-15 Journal: Journal of Translational Medicine [Category] 바이오마커, 유전자 메커니즘, [키워드] Accuracy addition adjuvant advance adverse events Algorithm anti-CTLA-4 Anti-PD-1 approach approved Biomarker Biomarkers biopsy BRAF BRAF inhibitor bridge cancers Cell characterized Chemotherapy clinically Combination Combination strategies combination therapy combination treatment COVID-19 pandemic development Diagnosis Drug administration Efficacy effort Evidence feature genomic help Host immune response immune Immune checkpoint inhibitor immune response Immunotherapy improve diagnostics Improved Italy lesions management mechanism mechanism of action MEK inhibitor Melanoma Naples Neoadjuvant oncogenic overcome Patient patients platform Precision predict Predictive Radiotherapy Research robust specific treatment survival systemic and local target target therapy tested therapeutic therapeutic agent therapy translational treatment regimens tumor immunity tumor microenvironment Vaccine viruses [DOI] 10.1186/s12967-022-03592-4 PMC 바로가기